Exact Sciences Licenses Mayo Clinic IP; Closes $8.2M Placement

Exact gained exclusive rights to technology developed by the Mayo Clinic's David Ahlquist relating to sample processing, analytical testing, and data analysis for non-invasive, stool-based DNA screening for colorectal cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.